Loss of heterozygosity and SOSTDC1 in adult and pediatric renal tumors

Journal of Experimental and Clinical Cancer Research

Volumn 29, Issue 1, 2010, Pages

  Blish, Kimberly R ^a   Clausen, Kathryn A ^a   Hawkins, Gregory A ^a   Garvin, A Julian ^a   Willingham, Mark C ^a   Turner, Julie C ^a   Torti, Frank M ^a   Torti, Suzy V ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; BONE MORPHOGENETIC PROTEIN; PROTEIN; SOSTDC1 PROTEIN, HUMAN; WNT PROTEIN;

ADULT; ADULT DISEASE; ARTICLE; CELL STRAIN HEK293; CELLULAR DISTRIBUTION; CHILDHOOD CANCER; CHROMOSOME ABERRATION; DOWN REGULATION; GENE SEQUENCE; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; KIDNEY TUMOR; MAJOR CLINICAL STUDY; NEPHROBLASTOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SOSTDC1 GENE; TUMOR SUPPRESSOR GENE; CHILD; CHROMOSOME 7; GENETICS; METABOLISM; POLYMERASE CHAIN REACTION;

ADULT; CARCINOMA, RENAL CELL; CHILD; CHROMOSOMES, HUMAN, PAIR 7; GENES, WILMS TUMOR; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY NEOPLASMS; LOSS OF HETEROZYGOSITY; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEINS; SIGNAL TRANSDUCTION; WILMS TUMOR; WNT PROTEINS;

EID: 78149493711     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-29-147     Document Type: Article

References (44)

1. Wilms tumor. GJ Aune, Pediatr Rev 2008 29 142 143 discussion 143 10.1542/pir.29-4-142 18381484
2. Wilms' tumor in children: an overview. A Varan, Nephron Clin Pract 2008 108 83 90 10.1159/000113012 18187945
3. Focus on kidney cancer. WM Linehan B Zbar, Cancer Cell 2004 6 223 228 10.1016/j.ccr.2004.09.006 15380513
4. Molecular characterization of a 7p15-21 homozygous deletion in a Wilms tumor. K Sossey-Alaoui L Vieira D David MG Boavida JK Cowell, Genes Chromosomes Cancer 2003 36 1 6 10.1002/gcc.10133 12461744
5. Isochromosome 7q in adult Wilms' tumors: diagnostic and pathogenetic implications. BP Rubin MR Pins GP Nielsen S Rosen BL Hsi JA Fletcher AA Renshaw, Am J Surg Pathol 2000 24 1663 1669 10.1097/00000478-200012000-00011 11117788
6. Patterns of aneuploidy in stage IV clear cell renal cell carcinoma revealed by comparative genomic hybridization and spectral karyotyping. CP Pavlovich H Padilla-Nash D Wangsa ML Nickerson V Matrosova WM Linehan T Ried JL Phillips, Genes Chromosomes Cancer 2003 37 252 260 10.1002/gcc.10209 12759923
7. Chromosomal imbalances in papillary renal cell carcinoma: genetic differences between histological subtypes. F Jiang J Richter P Schraml L Bubendorf T Gasser G Sauter MJ Mihatsch H Moch, Am J Pathol 1998 153 1467 1473 9811338
8. Comparison of type I and II papillary renal cell carcinoma (RCC) and clear cell RCC. M Waldert A Haitel M Marberger D Katzenbeisser M Ozsoy E Stadler M Remzi, BJU Int 2008 102 1381 1384 18782311
9. Chromosomal abnormalities of clear cell renal cell carcinoma: frequent gain of chromosome 7. N Kuroda M Tamura T Shiotsu S Nakamura T Taguchi A Tominaga O Hes M Michal C Kawada T Shuin, et al. Pathol Int 60 9 13 10.1111/j.1440-1827.2009.02467.x 20055946
10. Two candidate tumor suppressor genes, MEOX2 and SOSTDC1, identified in a 7p21 homozygous deletion region in a Wilms tumor. J Ohshima M Haruta Y Arai F Kasai Y Fujiwara T Ariga H Okita M Fukuzawa J Hata H Horie, et al. Genes Chromosomes Cancer 2009 48 1037 1050 10.1002/gcc.20705 19760604
11. The homeobox gene GAX activates p21WAF1/CIP1 expression in vascular endothelial cells through direct interaction with upstream AT-rich sequences. Y Chen AD Leal S Patel DH Gorski, J Biol Chem 2007 282 507 517 10.1074/jbc.M606604200 17074759
12. Characterization of wise protein and its molecular mechanism to interact with both Wnt and BMP signals. KB Lintern S Guidato A Rowe JW Saldanha N Itasaki, J Biol Chem 2009 284 23159 23168 10.1074/jbc.M109.025478 19553665
13. Identification of a secreted BMP antagonist, ectodin, integrating BMP, FGF, and SHH signals from the tooth enamel knot. J Laurikkala Y Kassai L Pakkasjarvi I Thesleff N Itoh, Dev Biol 2003 264 91 105 10.1016/j.ydbio.2003.08. 011 14623234
14. USAG-1: a bone morphogenetic protein antagonist abundantly expressed in the kidney. M Yanagita M Oka T Watabe H Iguchi A Niida S Takahashi T Akiyama K Miyazono M Yanagisawa T Sakurai, Biochem Biophys Res Commun 2004 316 490 500 10.1016/j.bbrc.2004.02.075 15020244
15. BMP antagonists: their roles in development and involvement in pathophysiology. M Yanagita, Cytokine Growth Factor Rev 2005 16 309 317 10.1016/j.cytogfr.2005.02.007 15951218
16. A human bone morphogenetic protein antagonist is down-regulated in renal cancer. KR Blish W Wang MC Willingham W Du CE Birse SR Krishnan JC Brown GA Hawkins AJ Garvin RB D'Agostino Jr, et al. Mol Biol Cell 2008 19 457 464 10.1091/mbc.E07-05-0433 18032587
17. Bone morphogenetic protein signalling in colorectal cancer. JC Hardwick LL Kodach GJ Offerhaus GR van den Brink, Nat Rev Cancer 2008 8 806 812 10.1038/nrc2467 18756288
18. Bone morphogenetic protein signaling enhances invasion and bone metastasis of breast cancer cells through Smad pathway. Y Katsuno A Hanyu H Kanda Y Ishikawa F Akiyama T Iwase E Ogata S Ehata K Miyazono T Imamura, Oncogene 2008 27 6322 6333 10.1038/onc.2008.232 18663362
19. Osteoblasts-derived BMP-2 enhances the motility of prostate cancer cells via activation of integrins. TH Lai YC Fong WM Fu RS Yang CH Tang, Prostate 2008 68 1341 1353 10.1002/pros.20799 18512729
20. Decreased expression of bone morphogenetic protein (BMP) receptor type II correlates with insensitivity to BMP-6 in human renal cell carcinoma cells. IY Kim DH Lee DK Lee BC Kim HT Kim FS Leach WM Linehan RA Morton SJ Kim, Clin Cancer Res 2003 9 6046 6051 14676131
21. Wnt signalling in stem cells and cancer. T Reya H Clevers, Nature 2005 434 843 850 10.1038/nature03319 15829953 (Pubitemid 40558990)
22. Recent advances in Wilms tumor genetics. JS Dome MJ Coppes, Curr Opin Pediatr 2002 14 5 11 10.1097/00008480-200202000-00002 11880727
23. Wnt signaling in renal cancer. H Guillen-Ahlers, Curr Drug Targets 2008 9 591 600 10.2174/138945008784911813 18673245
24. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. P Chomczynski N Sacchi, Anal Biochem 1987 162 156 159 10.1016/0003-2697(87)90021-2 2440339
25. Wnt signaling and breast cancer. LR Howe AM Brown, Cancer Biol Ther 2004 3 36 41 14739782
26. The UCSC Genome Browser Database: 2008 update. D Karolchik RM Kuhn R Baertsch GP Barber H Clawson M Diekhans B Giardine RA Harte AS Hinrichs F Hsu, et al. Nucleic Acids Res 2008 36 773 779 10.1093/nar/gkm966 18086701
27. The human genome browser at UCSC. WJ Kent CW Sugnet TS Furey KM Roskin TH Pringle AM Zahler D Haussler, Genome Res 2002 12 996 1006 12045153
28. Reversing the effects of formalin fixation with citraconic anhydride and heat: a universal antigen retrieval method. S Namimatsu M Ghazizadeh Y Sugisaki, J Histochem Cytochem 2005 53 3 11 10.1369/jhc.4C6466.2005 15637333
29. ONCOMINE: a cancer microarray database and integrated data-mining platform. DR Rhodes J Yu K Shanker N Deshpande R Varambally D Ghosh T Barrette A Pandey AM Chinnaiyan, Neoplasia 2004 6 1 6 15068665
30. Infrequent mutation of the WT1 gene in 77 Wilms' Tumors. M Gessler A Konig K Arden P Grundy S Orkin S Sallan C Peters S Ruyle J Mandell F Li, et al. Hum Mutat 1994 3 212 222 10.1002/humu.1380030307 8019557 (Pubitemid 24122238)
31. Mutational activation of the beta-catenin proto-oncogene is a common event in the development of Wilms' tumors. R Koesters R Ridder A Kopp-Schneider D Betts V Adams F Niggli J Briner M von Knebel Doeberitz, Cancer Res 1999 59 3880 3882 10463574
32. Frequent association of beta-catenin and WT1 mutations in Wilms tumors. S Maiti R Alam CI Amos V Huff, Cancer Res 2000 60 6288 6292 11103785
33. Loss of heterozygosity at 7p in Wilms' tumour development. RM Powlesland AK Charles KT Malik PA Reynolds S Pires M Boavida KW Brown, Br J Cancer 2000 82 323 329 10.1054/bjoc.1999.0922 10646884
34. Loss of heterozygosity on chromosome 16 in sporadic Wilms' tumour. RG Grundy J Pritchard P Scambler JK Cowell, Br J Cancer 1998 78 1181 1187 9820177 (Pubitemid 28479148)
35. The serine-threonine protein phosphatase PPM1 D is frequently activated through amplification in aggressive primary breast tumours. J Rauta EL Alarmo P Kauraniemi R Karhu T Kuukasjarvi A Kallioniemi, Breast Cancer Res Treat 2006 95 257 263 10.1007/s10549-005-9017-7 16254685
36. Detection of large-scale variation in the human genome. AJ Iafrate L Feuk MN Rivera ML Listewnik PK Donahoe Y Qi SW Scherer C Lee, Nat Genet 2004 36 949 951 10.1038/ng1416 15286789
37. WT1 splicing alterations in Wilms' tumors. D Baudry M Hamelin MO Cabanis JC Fournet MF Tournade S Sarnacki C Junien C Jeanpierre, Clin Cancer Res 2000 6 3957 3965 11051244
38. Different mechanisms cause imprinting defects at the IGF2/H19 locus in Beckwith-Wiedemann syndrome and Wilms' tumour. F Cerrato A Sparago G Verde A De Crescenzo V Citro MV Cubellis MM Rinaldi L Boccuto G Neri C Magnani, et al. Hum Mol Genet 2008 17 1427 1435 10.1093/hmg/ddn031 18245780
39. Duplication of paternal IGF2 or loss of maternal IGF2 imprinting occurs in half of Wilms tumors with various structural WT1 abnormalities. M Haruta Y Arai W Sugawara N Watanabe S Honda J Ohshima H Soejima H Nakadate H Okita J Hata, et al. Genes Chromosomes Cancer 2008 47 712 727 10.1002/gcc.20572 18464243
40. High-resolution DNA copy number and gene expression analyses distinguish chromophobe renal cell carcinomas and renal oncocytomas. MV Yusenko RP Kuiper T Boethe B Ljungberg AG van Kessel G Kovacs, BMC Cancer 2009 9 152 10.1186/1471-2407-9-152 19445733
41. Clear cell sarcoma of the kidney: up-regulation of neural markers with activation of the sonic hedgehog and Akt pathways. C Cutcliffe D Kersey CC Huang Y Zeng D Walterhouse EJ Perlman, Clin Cancer Res 2005 11 7986 7994 10.1158/1078-0432.CCR-05-1354 16299227
42. Previously unidentified changes in renal cell carcinoma gene expression identified by parametric analysis of microarray data. ME Lenburg LS Liou NP Gerry GM Frampton HT Cohen MF Christman, BMC Cancer 2003 3 31 10.1186/1471-2407-3-31 14641932
43. Secreted frizzled-related protein 1 loss contributes to tumor phenotype of clear cell renal cell carcinoma. ML Gumz H Zou PA Kreinest AC Childs LS Belmonte SN LeGrand KJ Wu BA Luxon M Sinha AS Parker, et al. Clin Cancer Res 2007 13 4740 4749 10.1158/1078-0432.CCR-07-0143 17699851
44. Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney. R Beroukhim JP Brunet A Di Napoli KD Mertz A Seeley MM Pires D Linhart RA Worrell H Moch MA Rubin, et al. Cancer Res 2009 69 4674 4681 10.1158/0008-5472.CAN-09- 0146 19470766